Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 35Terminated 11Active not recruiting 7Unknown 5Withdrawn 2Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 1Neoplasm Metastasis 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Pharmacogenomic Testing × Clear all
NCT00936832 2022-08-30

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Federation Francophone de Cancerologie Digestive

Phase 2 Withdrawn
Gastrointestinal

Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡